Cytosine deaminase herpes simplex virus-1/thymidine kinase fusion gene therapy

Drug Profile

Cytosine deaminase herpes simplex virus-1/thymidine kinase fusion gene therapy

Alternative Names: Ad5-CD/TKrep; Ad5-yCD/mutTKSR39rep-ADP; Radiation-sensitising gene therapy - NewGenPharm/Henry Ford Health System; Theragene

Latest Information Update: 22 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Henry Ford Health System
  • Developer Henry Ford Health System; NewGenPharm
  • Class Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • No development reported Prostate cancer

Most Recent Events

  • 01 Aug 2016 Seoul National University Hospital initiates enrolment in a phase trial for Pancreatic cancer (Combination therapy) in South Korea (Parenteral) (NCT02894944)
  • 26 Nov 2015 No recent reports on development identified - Phase-II for Prostate cancer in South Korea (Intraprostatic)
  • 26 Nov 2015 No recent reports on development identified - Phase-III for Prostate cancer in USA (Intraprostatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top